Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 11/2020

01-11-2020 | Prostate Cancer | Research article

Urinary microRNAs expression in prostate cancer diagnosis: a systematic review

Authors: R. M. Paiva, D. A. G. Zauli, B. S. Neto, I. S. Brum

Published in: Clinical and Translational Oncology | Issue 11/2020

Login to get access

Abstract

Purpose

Circulating microRNAs (miRNAs) have been shown to have the potential as noninvasive diagnosis biomarkers in several types of cancers, including prostate cancer (PCa). Urine-based miRNA biomarkers have been researched as an alternative tool in PCa diagnosis. However, few studies have performed miRNA detection in urine samples from PCa patients, as well as low numbers of miRNAs have been assayed, and there is a lack of standard strategies for validation. In this context, we conducted an in-depth literature review focusing on miRNAs isolated from urine samples that may contribute to the diagnosis of PCa.

Methods

A systematic review was performed searching the PubMed, Lilacs and Cochrane Library databases for articles focused on the value of significantly deregulated miRNAs as biomarkers in PCa patients.

Results

Only 18 primary manuscripts were included in this review, according to the search criteria. Our results suggest that miR-21-5p, miR-141-3p, miR-375 and miR-574-3p should be considered as potential urinary biomarkers for the diagnosis of PCa.

Conclusion

These results suggested that large-scale prospective studies are still needed to validate our findings, using standardized protocols for analysis.
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRefPubMed
2.
Payne H, Cornford P. Prostate-specific antigen: an evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol Semin Orig Investig. 2011;29:593–601.
3.
Woolf SH. The accuracy and effectiveness of routine population screening with mammography, prostate-specific antigen, and prenatal ultrasound: a review of published scientific evidence. Int J Technol Assess Health Care. 2001;17:275–304.PubMedCrossRef
4.
Hoffman RM, Gilliland FD, Adams-Cameron M, Hunt WC, Key CR. Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract. 2002;3:19.PubMedPubMedCentralCrossRef
5.
Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75:843–54.PubMedCrossRef
6.
7.
Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta. 2010;1803:1231–43.PubMedCrossRef
8.
Wang YL, Wu S, Jiang B, Yin FF, Zheng SS, Hou SC. Role of MicroRNAs in prostate cancer pathogenesis. Clin Genitourin Cancer. 2015;13:261–70.PubMedCrossRef
9.
Esquela-kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6:259–69.PubMedCrossRef
10.
Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101:2999–3004.PubMedPubMedCentralCrossRef
11.
Balacescu O, Dumitrescu RG, Marian C. MicroRNAs role in prostate cancer. Methods Mol Biol. 2018;1856:103–17.PubMedCrossRef
12.
Di Meo A, Bartlett J, Cheng Y, Pasic MD, Yousef GM. Liquid biopsy: a step forward towards precision medicine in urologic malignancies. Mol Cancer. 2017;16:80.PubMedPubMedCentralCrossRef
13.
Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8:467–77.PubMedPubMedCentralCrossRef
14.
15.
Yin C, Fang C, Weng H, Yuan C, Wang F. Circulating microRNAs as novel biomarkers in the diagnosis of prostate cancer: a systematic review and meta-analysis. Int Urol Nephrol. 2016;48:1087–95.PubMedCrossRef
16.
McDonald AC, Vira M, Shen J, Sanda M, Raman JD, Liao J, et al. Circulating microRNAs in plasma as potential biomarkers for the early detection of prostate cancer. Prostate. 2018;78:411–8.PubMedCrossRef
17.
Souza MF, Kuasne H, Barros-Filho MC, Cilião HL, Marchi FA, Fuganti PE, et al. Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer. PLoS ONE. 2017;12:e0184094.PubMedPubMedCentralCrossRef
18.
Fredsøe J, Rasmussen AKI, Thomsen AR, Mouritzen P, Høyer S, Borre M, et al. Diagnostic and prognostic microRNA biomarkers for prostate cancer in cell-free urine. Eur Urol Focus. 2018;4:825–33.PubMedCrossRef
19.
Stuopelyte K, Daniunaite K, Bakavicius A, Lazutka JR, Jankevicius F, Jarmalaite S. The utility of urine-circulating miRNAs for detection of prostate cancer. Br J Cancer. 2016;115:707–15.PubMedPubMedCentralCrossRef
20.
Salido-Guadarrama AI, Morales-Montor JG, Rangel-Escareño C, Langley E, Peralta-Zaragoza O, Cruz Colin JL, et al. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone. Mol Med Rep. 2016;13:4549–60.PubMedPubMedCentralCrossRef
21.
Bryant RJ, Pawlowski T, Catto JWF, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. Br J Cancer. 2012;106:768–74.PubMedPubMedCentralCrossRef
22.
Casanova-Salas I, Rubio-Briones J, Calatrava A, Mancarella C, Masiá E, Casanova J, et al. Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J Urol. 2014;192:252–9.PubMedCrossRef
23.
Srivastava A, Goldberger H, Dimtchev A, Ramalinga M, Chijioke J, Marian C, et al. MicroRNA profiling in prostate cancer - the diagnostic potential of urinary miR-205 and miR-214. PLoS One. 2013;8:e76994.PubMedPubMedCentralCrossRef
24.
Korzeniewski N, Tosev G, Pahernik S, Hadaschik B, Hohenfellner M, Duensing S. Identification of cell-free microRNAs in the urine of patients with prostate cancer. Urol Oncol. 2015;33:16.e17–e22.CrossRef
25.
Samsonov R, Shtam T, Burdakov V, Glotov A, Tsyrlina E, Berstein L, et al. Lectin-induced agglutination method of urinary exosomes isolation followed by mi-RNA analysis: application for prostate cancer diagnostic. Prostate. 2016;76:68–79.PubMedCrossRef
26.
Foj L, Ferrer F, Serra M, Arévalo A, Gavagnach M, Giménez N, et al. Exosomal and non-exosomal urinary miRNAs in prostate cancer detection and prognosis. Prostate. 2017;77:573–83.PubMedCrossRef
27.
Bryzgunova OE, Zaripov MM, Skvortsova TE, Lekchnov EA, Grigoreva AE, Zaporozhchenko IA, et al. Comparative study of extracellular vesicles from the urine of healthy individuals and prostate cancer patients. PLoS ONE. 2016;11:e0157566.PubMedPubMedCentralCrossRef
28.
Nouri M, Ratther E, Stylianou N, Nelson CC, Hollier BG, Williams ED. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention. Front Oncol. 2014;4:370.PubMedPubMedCentralCrossRef
29.
Karatas OF, Guzel E, Suer I, Ekici ID, Caskurlu T, Creighton CJ, et al. MiR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer. PLoS ONE. 2014;9:e98675.PubMedPubMedCentralCrossRef
30.
Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.PubMedCrossRef
31.
Mekhail SM, Yousef PG, Jackinsky SW, Pasic M, Yousef GM. MiRNA in prostate cancer: new prospects for old challenges. EJIFCC. 2014;25:79–98.PubMedPubMedCentral
32.
Shah JS, Soon PS, Marsh DJ. Comparison of methodologies to detect low levels of hemolysis in serum for accurate assessment of serum microRNAs. PLoS ONE. 2016;11:e0153200.PubMedPubMedCentralCrossRef
33.
Tiberio P, Callari M, Angeloni V, Daidone MG, Appierto V. Challenges in using circulating miRNAs as cancer biomarkers. Biomed Res Int. 2015;2015:731479.PubMedPubMedCentralCrossRef
34.
Brett SI, Kim Y, Biggs CN, Chin JL, Leong HS. Extracellular vesicles such as prostate cancer cell fragments as a fluid biopsy for prostate cancer. Prostate Cancer Prostatic Dis. 2015;18:213–20.PubMedCrossRef
35.
36.
37.
Koppers-Lalic D, Hackenberg M, de Menezes R, Misovic B, Wachalska M, Geldof A, et al. Non-invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles. Oncotarget. 2016;7:22566–78.PubMedPubMedCentralCrossRef
38.
Xu Y, Qin S, An T, Tang Y, Huang Y, Zheng L. MiR-145 detection in urinary extracellular vesicles increase diagnostic efficiency of prostate cancer based on hydrostatic filtration dialysis method. Prostate. 2017;77:1167–75.PubMedCrossRef
39.
Lekchnov EA, Amelina EV, Bryzgunova OE, Zaporozhchenko IA, Konoshenko MY, Yarmoschuk SV, et al. Searching for the novel specific predictors of prostate cancer in urine: the analysis of 84 miRNA expression. Int J Mol Sci. 2018;19:E4088.PubMedCrossRef
40.
El-Khoury V, Pierson S, Kaoma T, Bernardin F, Berchem G. Assessing cellular and circulating miRNA recovery: the impact of the RNA isolation method and the quantity of input material. Sci Rep. 2016;6:19529.PubMedPubMedCentralCrossRef
41.
Brunet-Vega A, Pericay C, Quílez ME, Ramírez-Lázaro MJ, Calvet X, Lario S. Variability in microRNA recovery from plasma: comparison of five commercial kits. Anal Biochem. 2015;488:28–35.PubMedCrossRef
42.
Git A, Dvinge H, Salmon-Divon M, Osborne M, Kutter C, Hadfield J, et al. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA. 2010;16:991–1006.PubMedPubMedCentralCrossRef
43.
44.
Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, et al. Minimum information about a microarray experiment (MIAME)—toward standards for microarray data. Nat Genet. 2001;29:365–71.PubMedCrossRef
45.
Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611–22.PubMedCrossRef
46.
Ghorbanmehr N, Gharbi S, Korsching E, Tavallaei M, Einollahi B, Mowla SJ. MiR-21-5p, miR-141-3p, and miR-205-5p levels in urine—promising biomarkers for the identification of prostate and bladder cancer. Prostate. 2019;79:88–95.PubMedCrossRef
47.
Balacescu O, Petrut B, Tudoran O, Feflea D, Balacescu L, Anghel A, et al. Urinary microRNAs for prostate cancer diagnosis, prognosis, and treatment response: are we there yet? Wiley Interdiscip Rev RNA. 2017;8:e1438.CrossRef
48.
49.
Agaoglu FY, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumor Biol. 2011;32:583–8.CrossRef
50.
Filella X, Foj L. MiRNAs as novel biomarkers in the management of prostate cancer. Clin Chem Lab Med. 2017;55:715–36.PubMedCrossRef
51.
Medina-Villaamil V, Martínez-Breijo S, Portela-Pereira P, Quindós-Varela M, Santamarina-Caínzoz I, Antón-Aparicio LM, et al. MicroARN circulantes en sangre de pacientes con cáncer de próstata. Actas Urológicas Españolas. 2014;38:633–9.PubMedCrossRef
52.
Sharma N, Baruah MM. The microRNA signatures: aberrantly expressed miRNAs in prostate cancer. Clin Transl Oncol. 2019;21:126–44.PubMedCrossRef
53.
Yang Y, Guo JX, Shao ZQ. MiR-21 targets and inhibits tumor supressor gene PTEN to promote prostate cancer cell proliferation and invasion: an experimental study. Asian Pac J Trop Med. 2017;10:87–91.PubMedCrossRef
54.
Li JZ, Li J, Wang HQ, Li X, Wen B, Wang YJ. MiR-141-3p promotes prostate cancer cell proliferation through inhibiting kruppel-like factor-9 expression. Biochem Biophys Res Commun. 2017;482:1381–6.PubMedCrossRef
55.
Pickl JMA, Tichy D, Kuryshev VY, Tolstov Y, Falkenstein M, Schüler J, et al. Ago-RIP-Seq identifies polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression. Oncotarget. 2016;7:59589–603.PubMedPubMedCentralCrossRef
56.
Selth LA, Das R, Townley SL, Coutinho I, Hanson AR, Centenera MM, et al. A ZEB1-miR-375-YAP1 pathway regulates epithelial plasticity in prostate cancer. Oncogene. 2017;36:24–34.PubMedCrossRef
57.
Rodríguez M, Bajo-Santos C, Hessvik NP, Lorenz S, Fromm B, Berge V, et al. Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol Cancer. 2017;16:156.PubMedPubMedCentralCrossRef
58.
Filella X, Foj L. Prostate cancer detection and prognosis: from prostate specific antigen (PSA) to exosomal biomarkers. Int J Mol Sci. 2016;17:E1784.PubMedCrossRef
59.
Wani S, Kaul D, Mavuduru RS, Kakkar N, Bhatia A. Urinary-exosomal miR-2909: a novel pathognomonic trait of prostate cancer severity. J Biotechnol. 2017;259:135–9.PubMedCrossRef
60.
Stephan C, Jung M, Rabenhorst S, Kilic E, Jung K. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue. Clin Chem Lab Med. 2015;53:1109–18.PubMed
61.
Haj-Ahmad TA, Abdalla MAK, Haj-Ahmad Y. Potential urinary miRNA biomarker candidates for the accurate detection of prostate cancer among benign prostatic hyperplasia patients. J Cancer. 2014;5:182–91.PubMedPubMedCentralCrossRef
62.
Guelfi G, Cochetti G, Stefanetti V, Zampini D, Diverio S, Boni A, et al. Next generation sequencing of urine exfoliated cells: an approach of prostate cancer microRNAs research. Sci Rep. 2018;8:7111.PubMedPubMedCentralCrossRef
Metadata
Title
Urinary microRNAs expression in prostate cancer diagnosis: a systematic review
Authors
R. M. Paiva
D. A. G. Zauli
B. S. Neto
I. S. Brum
Publication date
01-11-2020
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 11/2020
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02349-z

Other articles of this Issue 11/2020

Clinical and Translational Oncology 11/2020 Go to the issue

Research Article

Immune status and the efficacy of adjuvant radiotherapy for patients with localized Merkel cell carcinoma of the head and neck

Research Article

Radiation-induced lymphopenia: the main aspects to consider in immunotherapy trials for endometrial and cervical cancer patients

Review Article

The role of macrophages during breast cancer development and response to chemotherapy

Research Article

The effectiveness and safety of thromboprophylaxis in cancer patients based on Khorana score: a meta-analysis and systematic review of randomized controlled trials

Correspondence

Radiotherapy after prostatectomy in high‑risk prostate cancer

Brief Research Article

Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits